According to researchers at the Wistar Institute in Philadelphia, PA, current COVID-19 vaccines are strong tools in the fight against the ongoing pandemic, but they have their limitations. Without a booster shot, the efficacy of the first and second dose can wane over time, and the vaccine may be less effective against new variants.
Scientists at the Wistar Institute have developed a novel vaccine that relies on self-assembling nanoparticles and DNA delivery technology. The Wistar vaccine can also be stored at room temperature, as opposed to mRNA vaccines, which must be stored in refrigerators, making it potentially easier to transport to remote or developing locations.
To make the novel vaccine, the researchers created a new algorithm for designing glycans, (i.e., polysaccharides) on the surface of proteins, in an effort to model the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. They hope to inject this RBD into patients to produce an immune...
Would you like to access the complete CEP News Update?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.
